Extended-release PEG-luciferin allows for long-term imaging of firefly luciferase activity in vivo

Luminescence

Volumn 24, Issue 1, 2009, Pages 35-38

  Chandran, Sachin S ^a   Williams, Simon A ^b   Denmeade, Samuel R ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Johns Hopkins University   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

6 amino d luciferin; Imaging; Luciferase; PEG; Polyethylene glycol

Indexed keywords

CELL CULTURE; TUMORS;

6-AMINO-D-LUCIFERIN; D LUCIFERINS; EXTENDED RELEASE; FIREFLY LUCIFERASE; HALF LIVES; IN-VIVO; LONG-TERM IMAGING; LUCIFERASE; LUCIFERASE ACTIVITIES; NON DESTRUCTIVE;

BIOLUMINESCENCE;

ANIMALIA; MUS;

EID: 61349180802     PISSN: 15227235     EISSN: 15227243     Source Type: Journal    
DOI: 10.1002/bio.1060     Document Type: Article

References (12)

1. Wehrman TS, von Degenfeld G, Krutzik PO, Nolan GP, Blau HM. Luminescent imaging of β-galactosidase activity in living subjects using sequential reporter-enzyme luminescence. Nat. Methods 2006; 3: 295-301.
2. Liu JJ, Wang WG, Dicker DT, El-Deiry WS. Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin. Cancer Biol. Ther. 2005; 4: 885-892.
3. Monsees T, Miska W, Geiger R. Synthesis and characterization of a bioluminogenic substrate for α-chymotrypsin. Anal. Biochem. 1994; 221: 329-334.
4. Shinde R, Perkins J, Contag CH. Luciferin derivatives for enhanced in vitro and in vivo bioluminescence assays. Biochemistry 2006; 45: 11103-11112.
5. Wilson T, Hastings JW. Bioluminescence. Annu. Rev. Cell Dev. Biol. 1998; 14: 197-230.
6. Gross S, Abraham U, Prior JL, Herzog ED, Piwnica-Worms D. Continuous delivery of D-luciferin by implanted micro-osmotic pumps enables true real-time bioluminescence imaging of luciferase activity in vivo. Mol. Imaging 2007; 6: 121-130.
7. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46: 6387-6392.
8. Greenwald RB, Choe YH, McGuire J, Conover CD. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 2003; 55: 217-250.
9. Janssen S, Rosen DM, Ricklis RM, Dionne CA, Lilja H, Christensen SB, Isaacs JT, Denmeade SR. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. Prostate 2006; 66: 358-68.
10. Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L, Isaacs JT. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate 2006; 66: 1329-1338.
11. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB, Isaacs JT. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J. Natl Cancer. Inst. 2003; 95: 990-1000.
12. Chandran SS, Nan A, Rosen DM, Ghandehari H, Denmeade SR. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer. Mol. Cancer Ther. 2007; 6: 2928-2937.